ArticleOxidative medicine and cellular longevity2019
Low-Energy Extracorporeal Shock Wave Therapy Ameliorates Kidney Function in Diabetic Nephropathy.
Article in Oxidative medicine and cellular longevity, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- Low-intensity extracorporeal shockwave therapy in patients with diabetic kidney disease: a matched cohort study.International urology and nephrology · 2025Trial
- Low Intensity Extracorporeal Shock Wave Therapy as a Novel Treatment for Stress Urinary Incontinence: A Randomized-Controlled Clinical Study.Medicina (Kaunas, Lithuania) · 2021Trial
- Combined Mesenchymal Stem Cells and Low-Energy Shock Wave Therapy Significantly Reduced Inflammation, Oxidative Stress and Preserved Podocytes in Diabetic Nephropathy.Life (Basel, Switzerland) · 2026Article
- Low-intensity extracorporeal shock wave therapy ameliorates fibrosis and renal function in a preclinical model of chronic kidney disease.Anatomy & cell biology · 2026Article
- Common Pathophysiological Mechanisms and Treatment of Diabetic Gastroparesis.Journal of neurogastroenterology and motility · 2024Review
- Low-Intensity Extracorporeal Shockwave Therapy (LI-ESWT) in Renal Diseases: A Review of Animal and Human Studies.International journal of nephrology and renovascular disease · 2023Review
- lncRNA NEAT1-let 7b-P21 axis mediates the proliferation of neural stem cells culturedRegenerative therapy · 2022Article
- Microenergy acoustic pulses promotes muscle regeneration through in situ activation of muscle stem cells.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2022Article
- Use of the Shock Wave Therapy in Basic Research and Clinical Applications-From Bench to Bedsite.Biomedicines · 2022Review
- Effect of Li-ESWT on Testicular Tissue and Function in Androgen-Deficient Rat Model.Oxidative medicine and cellular longevity · 2022Article
- Combined Melatonin and Extracorporeal Shock Wave Therapy Enhances Podocyte Protection and Ameliorates Kidney Function in a Diabetic Nephropathy Rat Model.Antioxidants (Basel, Switzerland) · 2021Article
- Strategies to Get Drugs across Bladder Penetrating Barriers for Improving Bladder Cancer Therapy.Pharmaceutics · 2021Review
- Burdock Fructooligosaccharide Attenuates High Glucose-Induced Apoptosis and Oxidative Stress Injury in Renal Tubular Epithelial Cells.Frontiers in pharmacology · 2021Article
- Protective mechanism of apigenin in diabetic nephropathy is related to its regulation of miR-423-5P-USF2 axis.American journal of translational research · 2021Article
- Low-Intensity Shockwave Therapy (LI-ESWT) in Diabetic Kidney Disease: Results from an Open-Label Interventional Clinical Trial.International journal of nephrology and renovascular disease · 2021Article
- It Comes As a Shock: Kidney Repair Using Shockwave Therapy.Hypertension (Dallas, Tex. : 1979) · 2020Review
- Low-energy shock wave pretreatment recruit circulating endothelial progenitor cells to attenuate renal ischaemia reperfusion injury.Journal of cellular and molecular medicine · 2020Article
- Low-Energy Extracorporeal Shock Wave Ameliorates Streptozotocin Induced Diabetes and Promotes Pancreatic Beta Cells Regeneration in a Rat Model.International journal of molecular sciences · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetic nephropathy is the most common cause of end-stage renal disease. Traditional therapy for diabetic nephropathy has focused on supportive treatment, and there is no significant effective therapy. We investigated the effect of low-energy extracorporeal shock wave therapy on a diabetic nephropathy rat model.
methodsStreptozotocin-induced diabetic nephropathy rats were treated with six sessions of low-energy extracorporeal shock wave therapy (weekly for six consecutive weeks) or left untreated. We assessed urinary creatinine and albumin, glomerular volume, renal fibrosis, podocyte number, renal inflammation, oxidative stress, and tissue repair markers (SDF-1 and VEGF) six weeks after the completion of treatment.
resultsThe six-week low-energy extracorporeal shock wave therapy regimen decreased urinary albumin excretion as well as reduced glomerular hypertrophy and renal fibrosis in the rat model of diabetic nephropathy. Moreover, low-energy extracorporeal shock wave therapy increased podocyte number in diabetic nephropathy rats. This was likely primarily attributed to the fact that low-energy extracorporeal shock wave therapy reduced renal inflammation and oxidative stress as well as increased tissue repair potency and cell proliferation.
conclusionsLow-energy extracorporeal shock wave therapy preserved kidney function in diabetic nephropathy. Low-energy extracorporeal shock wave therapy may serve as a novel noninvasive and effective treatment of diabetic nephropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.